Trekrezan in 103 inpatients with ongoing symptoms after COVID-19
Comparison in people · 2022
- What was studied
- 103 hospital inpatients with ongoing symptoms after moderate or severe COVID-19. Background care plus Trekrezan: 53. Background care without adaptogens: 50.
- Main finding
- Mean MFI-20 fatigue scores fell from 44.5 to 31.9 with add-on Trekrezan and from 41.2 to 36.7 in the comparison group. Hospital stays averaged 11.4 vs 12.5 days.
MFI-20 fatigue score · 44.5 ± 13.9 to 31.9 ± 9.5 vs 41.2 ± 13.1 to 36.7 ± 6.4 · Days 8–10 · Table 2 lists p<0.001 without identifying the contrast in the table header.
Reported findings and study design
Open parallel-group hospital study. Patients were allocated by odd/even enrollment numbers. Assessments included MFI-20, lung diffusion capacity and oxygen saturation.
Population or model 103 hospital inpatients with ongoing symptoms after moderate or severe COVID-19. Background care plus Trekrezan: 53. Background care without adaptogens: 50.
Dose, route and schedule
Oral Trekrezan 600 mg on day 1, then 200 mg/day for seven days (2,000 mg total). The main assessment was at days 8–10.
Protocol source ↗ · Original journal PDF, methods and Table 2.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MFI-20 fatigue score | 44.5 ± 13.9 to 31.9 ± 9.5 vs 41.2 ± 13.1 to 36.7 ± 6.4 | Days 8–10 · Table 2 lists p<0.001 without identifying the contrast in the table header. |
| Hospital stay | 11.4 ± 1.7 vs 12.5 ± 1.6 days | Table 2 reports p<0.001. The table does not specify the statistical test for this row. |
| Lung diffusion capacity (% predicted) | 64.7 to 68.7 vs 63.8 to 67.9 | Both groups improved by roughly four percentage points. |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- Open comparison with predictable odd/even assignment. The groups began with different mean fatigue scores. Both groups received other care.
- This separate inpatient cohort used a different fatigue scale from the Zueva outpatient study.
Source details
Original journal PDF, methods and Table 2.
Sources checked
Citation
A. A. Zaitsev, N. A. Ternovskaya, E. A. Chelan, I. T. Kulagina, Y. A. Sidorov, V. I. Likhodiy. Trekrezan in 103 inpatients with ongoing symptoms after COVID-19 The Bulletin of Contemporary Clinical Medicine. 2022;15(1):26–33.
Study source ↗ · DOI 10.20969/VSKM.2022.15(1).26-33 · Bibliography entry · Link to this summary